Home>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>DuP 105

DuP 105

Catalog No.GC32267

DuP 105 is an orally active oxazolidinone, a new class of synthetic antimicrobial agent with activity against gram-positive bacteria.

Products are for research use only. Not for human use. We do not sell to patients.

DuP 105 Chemical Structure

Cas No.: 96800-41-8

Size Price Stock
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire
10mg Please Inquire Please Inquire
20mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

DuP 105 is an orally active oxazolidinone, a new class of synthetic antimicrobial agent with activity against gram-positive bacteria.

DuP 105 shows inhibitory activities against staphylococcal isolates and B. fragilis isolates with MIC90s of 4 to 16 μg/mL and 16 μg/mL[1]. DuP 105 MICs for 50% of the 216 gram-positive isolates tested (MIC50s) range from 4.0 to 16 μg/mL[2].

DuP 105 administered by either the oral or the parenteral route is protective against staphylococcal and streptococcal infections in mice with the 50% effective doses of 9 to 23 mg/kg[1].

[1]. Slee AM, et al. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 1987 Nov;31(11):1791-7. [2]. Barry AL, et al. In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents. Antimicrob Agents Chemother. 1988 Jan;32(1):150-2.

Reviews

Review for DuP 105

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DuP 105

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.